Articles about Covishield

The Drugs Controller General of India (DCGI) on Thursday granted approval for regular market sale to India's two most prevalent COVID-19 vaccines—COVAXIN and Covishield.

The Serum Institute of India is looking to launch a COVID-19 vaccine for children in six months, SII CEO Adar Poonawalla said Tuesday.

Seven COVID-19 vaccines are safe and stimulate a strong immune response when used as a booster jab to those who have already vaccinated, a study published in The Lancet said.

India on Thursday reported over 9,000 new COVID-19 cases with an active caseload of just under one lakh.

The United Kingdom has announced that Indians who are fully vaccinated with Covishield or any other UK-approved coronavirus vaccine will not have to quarantine upon arrival in Britain from Monday, October 11.

People who are fully inoculated and want to travel abroad will have a Co-WIN certificate with their full date of birth, official sources said on Saturday amid ongoing discussions between India and the UK over COVID-19 vaccination certificates.

The United Kingdom on Wednesday revised its travel advisory, listing Covishield as an approved COVID-19 vaccine.

India on Tuesday issued a sharp reaction to the United Kingdom's decision to not recognize Covishield as a legitimate COVID-19 vaccine.

India's External Affairs Minister S Jaishankar has pushed for a resolution of the COVID-19 quarantine issue faced by Indians in the United Kingdom.

Former Union ministers Jairam Ramesh and Shashi Tharoor on Monday slammed the UK's COVID-19-related travel rules under which Indians vaccinated with Covishield would still be treated as unvaccinated.

The Kerala High Court on Tuesday asked the Centre whether the 84-day gap between two doses of Covishield was based on the availability of the vaccine or its efficacy.

Serum Institute of India Chairman Cyrus Poonawalla on Friday said that taking a third or booster dose of Covishield, the coronavirus vaccine manufactured by his firm was desirable.

The Drugs Controller General of India (DCGI) has approved a proposal to conduct a study on the mixing of Covishield and COVAXIN COVID-19 vaccines.

A study conducted by the Indian Council of Medical Research (ICMR) has indicated that mixing and matching of COVID-19 vaccines Covishield and COVAXIN can yield better results.

The Delta variant is highly-transmissible and possibly leads to a more severe disease of COVID-19.

India is considering allowing the mixing of different COVID-19 vaccine doses in what could be the first mix-and-match inoculation.

The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) has given its go-ahead for conducting clinical trials involving the mixing and matching of Covishield and COVAXIN vaccine doses.

The Centre may soon reduce the 25% quota of COVID-19 vaccine supply for private facilities for their failure to pick up the earmarked quota.

The Centre has placed an order to procure 66 crore doses of Covishield and COVAXIN to be supplied between August and December this year, at a revised price of Rs. 205 and Rs. 215 per dose, respectively, excluding taxes, official sources said.

The European Medicines Agency (EMA) said it has not received any application for the authorization of the coronavirus vaccine Covishield.

The European Union's (EU) Digital COVID Certificate framework to allow easier, restriction-free movement of vaccinated travelers within European countries—excluding India-made Covishield and COVAXIN vaccines—comes into force on Thursday.

The Serum Institute of India (SII) has not yet applied for the approval of its coronavirus vaccine Covishield in the "Green Pass" issued by the European Union, according to a statement from the EU.

Covishield, the Indian version of the Oxford-AstraZeneca vaccine, has been excluded from the European Union's "Green Pass."

The Oxford-AstraZeneca vaccine, known in India as Covishield, may be associated with a small risk of developing a blood condition characterized by low platelet counts, according to a UK study.

After India's COVID-19 vaccination policy was updated this week, the central government is likely to renegotiate prices for vaccines, a report suggested.

The second dose of the Covishield vaccine will now be administered after 28 days to people who have to travel abroad for specific purposes, Punjab Health Minister Balbir Singh Sidhu said on Tuesday.

In a grave oversight, a group of villagers in Uttar Pradesh received two shots of two different vaccines: COVAXIN and Covishield (both two-dose vaccines).

The Karnataka government has set a goal to vaccinate all eligible people in the state by November end against coronavirus.

According to a series of early reports authored by scientists at the Indian Council of Medical Research (ICMR), COVAXIN and Covishield—vaccines deemed effective at generating an immune response against COVID-19—appear to generate only half as many antibodies against the B.1.617 variant.

A government expert panel has reportedly recommended raising the time gap between two doses of the COVID-19 vaccine Covishield to 12-16 weeks.

Maharashtra Health Minister Rajesh Tope on Monday urged Serum Institute of India Chief Executive Officer Adar Poonawalla to give priority to the state in providing its anti-coronavirus vaccine, Covishield, as the government was ready to purchase doses from the Pune-based company.

Adar Poonawalla, the CEO of the Serum Institute of India (SII), on Wednesday announced that the price of the COVID-19 vaccine Covishield was being reduced from Rs. 400 to Rs. 300 for states.

Maharashtra Health Minister Rajesh Tope today said that the state may receive its supply of the Covishield vaccine only after May 20.

Just as India is fighting a devastating second wave of coronavirus, the Joe Biden administration in the United States has pledged to help the Asian nation.

The central government on Wednesday said that a "very small" fraction of people have tested positive for COVID-19 after being vaccinated.

Serum Institute of India (SII) will sell Covishield at Rs. 400 per shot to states and at Rs. 600 to private hospitals, the Pune-based vaccine manufacturer said today.

The efficacy of the COVID-19 vaccine Covishield could increase to 90% if the two doses are given 2.5-3 months apart, Serum Institute of India CEO Adar Poonawalla said Monday.

A woman, whose age according to her Aadhaar Card is 118 years, has received her first dose of the COVID-19 vaccine in the Sagar district of Madhya Pradesh.

There is no heightened risk of blood clotting after vaccinations with indigenous COVAXIN and Covishield, the coronavirus vaccine developed by AstraZeneca and the University of Oxford, a top government committee concluded, reports Indian Express.

The time gap between two doses of the Covishield vaccine should be increased to six-to-eight weeks for improved results, the central government has written to all states and Union Territories.